NAVCO Pharmaceuticals Valuation
Is F0U undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of F0U when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate F0U's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate F0U's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for F0U?
Key metric: As F0U is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is F0U's PE Ratio? | |
|---|---|
| PE Ratio | 2.3x |
| Earnings | CA$489.32k |
| Market Cap | CA$1.14m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -1.3x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does F0U's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 18.8x | ||
ECX Epigenomics | 0.4x | n/a | €875.2k |
ENZN Enzon Pharmaceuticals | 22.8x | n/a | US$5.3m |
2INV 2invest | 12.7x | n/a | €63.8m |
532041 Hindustan Bio Sciences | 39.2x | n/a | ₹102.5m |
F0U NAVCO Pharmaceuticals | 2.3x | n/a | €1.1m |
Price-To-Earnings vs Peers: F0U is good value based on its Price-To-Earnings Ratio (2.3x) compared to the peer average (18.4x).
Price to Earnings Ratio vs Industry
How does F0U's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Earnings vs Industry: F0U is good value based on its Price-To-Earnings Ratio (2.3x) compared to the European Biotechs industry average (26.9x).
Price to Earnings Ratio vs Fair Ratio
What is F0U's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 2.3x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate F0U's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Regeneron Pharmaceuticals
US$80.0b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
RGO
US$705.00
7D
-7.1%
1Y
-3.8%
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.60
7D
-6.2%
1Y
90.0%
Merck
US$246.5b
Operates as a healthcare company worldwide.
6MK
US$93.40
7D
0.3%
1Y
-0.4%